Assessing the impact of single or short-term administration on a therapy's cost-effectiveness: a hypothetical disease-agnostic model.

This quantitative assessment showed the extent to which SST CEAs are highly sensitive to discounting, resulting in worse value assessments for SSTs than equivalent chronic therapies.